Study on the effects of an OCT2/MATE1 substrate (metformin) and inhibitor (cimetidine) on the exposure of trifluridine/tipiracil (Lonsurf) in patients with metastatic colorectal cancer (mCRC)
Latest Information Update: 30 May 2023
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Cimetidine; Metformin
- Indications Carcinoma; Colorectal cancer
- Focus Pharmacokinetics
- Acronyms SUMO trial
- Sponsors Servier
- 29 May 2023 Status changed from recruiting to completed.
- 01 Aug 2021 Planned End Date changed from 5 Jun 2022 to 31 Dec 2021.
- 22 Sep 2020 New trial record